Kymera Therapeutics, Inc. — Director's Dealing 2020

Aug 25, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kymera Therapeutics, Inc. (KYMR)
CIK: 0001815442
Period of Report: 2020-08-25

Reporting Person: Redmile Group, LLC (10% Owner)
Reporting Person: Green Jeremy (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-08-25	Common Stock	C	1630660	—	Acquired	1630660	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-25	Series C Convertible Preferred Stock	$	C	2600740	Disposed		Common Stock (1630660)	Indirect

Footnotes

F1: The Series C Convertible Preferred Stock converted into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-0.626998558 basis and had no expiration date.

F2: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.